Torrent Pharma Q3 PAT up 14% to Rs 249 crore riding on India, Brazil

Torrent Pharma's revenues came in at Rs 2,491 crore for the quarter under review. The Ebitda margins were at 29.1 per cent while gross margins were 71 per cent during Q3FY23

Torrent Pharmaceuticals
Torrent Pharma’s US revenues were up by 24 percent during the quarter to Rs 291 crore, while in constant currency terms it was up 13 percent.
Sohini Das Mumbai
1 min read Last Updated : Jan 25 2023 | 10:45 PM IST
Ahmedabad-based Torrent Pharmaceuticals posted a 14 per cent rise in net profit for the third quarter of the 2022-23 fiscal to Rs 249 crore on the back of good growth in the India and Brazil markets.

Torrent Pharma’s revenues came in at Rs 2,491 crore for the quarter under review. The Ebitda margins were at 29.1 per cent while gross margins were 71 per cent during Q3FY23.

India, Torrent’s key market, grew by 17 per cent to Rs 1,259 crore including revenues from the integration of its recently acquired outfit Curatio Healthcare (a dermatology firm). “Field force has been further expanded and medical representative strength now stands at 5,300 including Curatio divisions,” the company said.

Meanwhile, the Brazil revenues were up 36 per cent to Rs 248 crore. In constant currency terms, however, the revenues from Brazil were up 17 percent. The growth was aided by the performance of top brands and market share gain and strong momentum in the generic segment.

Torrent Pharma’s US revenues were up by 24 per cent during the quarter to Rs 291 crore, while in constant currency terms, it was up 13 per cent.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Torrent PharmaceuticalsQ3 resultsEBITDA

Next Story